Alimera Sciences (ALIM) Misses Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results
February 28, 2018 4:30 PM ESTGAAP Net Loss cut by 34% from $33.2 in 2016 to $22.0 million in 2017Adjusted EBITDA loss reduced by 61% from $22.8 million in 2016 to $8.8 million 2017Filed for Type II variation for uveitis in Europe for ILUVIEN in Q4 of 2017Refinanced previous debt facility with new debt facility from Solar Capital in January 2018
ATLANTA, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced financial results for the... More
